Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.
IM Cannabis Corp. reports developments tied to its medical cannabis platform serving patients in Israel and Germany. Company updates commonly address medical cannabis operations, regulatory and commercial positioning, operating and financial results, and the management of liquidity through note purchase agreements, convertible notes and common share purchase warrants.
Recurring IMCC news also includes Nasdaq listing-compliance notices, board and executive appointments, shareholder or governance matters, and disclosures related to material agreements and capital structure. The company’s announcements frame IM Cannabis as an international medical cannabis issuer with cross-border supply and compliance considerations in regulated cannabis markets.
IM Cannabis Corp. (CSE:IMCC) reported Q4 2020 revenues of $4.9 million with a gross margin of 57%. For FY 2020, revenues reached $15.9 million, a 75% increase from 2019. Preliminary Q1 2021 revenues are expected between $8.5 to $9.0 million. Q2 2021 outlook anticipates $17 to $19 million due to growth in Israel and Germany, and contributions from the acquisition of Trichome Financial Corp. Net losses for FY 2020 were approximately $28.7 million, driven by revaluation of warrants and operational costs. The company also proposed an acquisition of MYM Nutraceuticals, expected to complete by Q2 2021.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) announced a new supply agreement involving its subsidiary, Adjupharm, and Northern Green Canada (NGC), enhancing its product offerings in the German medical cannabis market. This partnership strengthens Adjupharm's distribution capabilities across over 6,000 pharmacies. The deal positions IMC for increased growth as NGC, a EU GMP-certified producer, provides high-quality medical cannabis. Additionally, IMC disclosed the termination of a purchase agreement with Zur Rose Pharma effective March 30, 2021.
IM Cannabis Corp. (NASDAQ: IMCC) has announced its acquisition of MYM Nutraceuticals Inc. and its subsidiary Highland Grow Inc. This deal is projected to enhance IMC's position in the premium cannabis market, with Highland Grow expected to contribute $29 million to $38 million in net revenue in 2021 and 2022. The purchase price values Highland Grow at 2.3x net revenue and 6.7x EBITDA. The transaction is anticipated to be immediately accretive and will provide significant distribution synergies and enhanced product offerings.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) has filed a final short form base shelf prospectus with Canadian securities authorities and a corresponding registration statement with the SEC. This will permit the Company to offer up to US$250 million in securities over a 25-month period. Proceeds may be utilized for corporate purposes, capital expenditures, and acquisitions. The shelf prospectus also allows for 'at-the-market' distributions via the CSE and NASDAQ. Copies of the prospectus are available on SEDAR and EDGAR.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) has filed a preliminary short form base shelf prospectus and a corresponding registration statement with the SEC. This initiative aims to enhance financial flexibility, allowing the company to offer up to US$250 million in various securities within a 25-month period upon regulatory effectiveness. The proceeds from any offerings could support general corporate purposes, capital expenditures, and acquisitions. The Shelf Prospectus could also facilitate an 'at-the-market distribution' through the CSE or NASDAQ.
IM Cannabis Corp. (IMCC) has entered a multi-year supply agreement with GTEC Holdings Ltd. to import premium high-THC medical cannabis flower into Israel, strengthening its product offerings in one of the largest medical cannabis markets globally. The imports will commence in Q2 2021, subject to regulatory approvals, allowing IMC to launch a new category of indoor cannabis products under its established brand. This strategic partnership enhances IMC's international supply network and positions it favorably in the growing demand for imported cannabis in Israel.
IM Cannabis Corp. (CSE:IMCC) announced its shares will commence trading on the NASDAQ Capital Market today, marking it as the first Israeli medical cannabis operator to do so. This listing aims to enhance access to investments and improve liquidity for shareholders. IMC operates in Israel and Germany, with plans to expand into Canada post-acquisition of Trichome Financial. In Q3 2020, IMC reported $11 million in revenue, achieving 67% year-over-year growth. The company aims for long-term shareholder value through growth strategies and prudent capital allocation.